Day One to Report Second Quarter 2025 Financial Results Tuesday, August 5, 2025
Day One Biopharmaceuticals (NASDAQ: DAWN), a company focused on developing targeted therapies for life-threatening diseases, has scheduled its Q2 2025 financial results conference call and webcast for Tuesday, August 5, 2025, at 4:30 p.m. ET.
The event will include a discussion of financial results and corporate updates. Investors can access the live webcast through Day One's Events page, and a replay will be available for 30 days following the presentation.
Day One Biopharmaceuticals (NASDAQ: DAWN), un'azienda specializzata nello sviluppo di terapie mirate per malattie potenzialmente letali, ha programmato la conferenza telefonica e la trasmissione in webcast dei risultati finanziari del secondo trimestre 2025 per martedì 5 agosto 2025, alle 16:30 ET.
L'evento includerà una discussione sui risultati finanziari e aggiornamenti aziendali. Gli investitori potranno accedere alla diretta streaming tramite la pagina Eventi di Day One, e la registrazione sarà disponibile per 30 giorni dopo la presentazione.
Day One Biopharmaceuticals (NASDAQ: DAWN), una empresa enfocada en desarrollar terapias dirigidas para enfermedades potencialmente mortales, ha programado su llamada y transmisión web para los resultados financieros del segundo trimestre de 2025 el martes 5 de agosto de 2025 a las 4:30 p.m. ET.
El evento incluirá una discusión sobre los resultados financieros y actualizaciones corporativas. Los inversores podrán acceder a la transmisión en vivo a través de la página de Eventos de Day One, y la repetición estará disponible durante 30 días después de la presentación.
Day One Biopharmaceuticals (NASDAQ: DAWN)는 생명을 위협하는 질병에 대한 표적 치료제를 개발하는 회사로, 2025년 2분기 재무 실적 컨퍼런스 콜 및 웹캐스트를 2025년 8월 5일 화요일 오후 4시 30분(동부시간)에 예정했습니다.
이번 행사에서는 재무 실적과 회사 최신 정보를 논의할 예정입니다. 투자자들은 Day One의 이벤트 페이지를 통해 실시간 웹캐스트에 접속할 수 있으며, 발표 후 30일간 다시보기가 제공됩니다.
Day One Biopharmaceuticals (NASDAQ: DAWN), une société spécialisée dans le développement de thérapies ciblées pour des maladies potentiellement mortelles, a programmé sa conférence téléphonique et webcast des résultats financiers du deuxième trimestre 2025 pour le mardi 5 août 2025 à 16h30 ET.
L'événement comprendra une discussion sur les résultats financiers et des mises à jour de l'entreprise. Les investisseurs pourront accéder au webcast en direct via la page Événements de Day One, et une rediffusion sera disponible pendant 30 jours après la présentation.
Day One Biopharmaceuticals (NASDAQ: DAWN), ein Unternehmen, das sich auf die Entwicklung zielgerichteter Therapien für lebensbedrohliche Krankheiten spezialisiert hat, hat seine Finanzergebnisse für das zweite Quartal 2025 für Dienstag, den 5. August 2025, um 16:30 Uhr ET angesetzt.
Die Veranstaltung beinhaltet eine Diskussion der Finanzergebnisse und Unternehmensupdates. Investoren können über die Eventseite von Day One auf das Live-Webcast zugreifen, und eine Aufzeichnung wird für 30 Tage nach der Präsentation verfügbar sein.
- None.
- None.
BRISBANE, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Day One Biopharmaceuticals (Nasdaq: DAWN) (“Day One” or the “Company”), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, today announced it will host a live conference call and webcast on Tuesday, August 5, 2025 at 4:30 p.m. ET to report financial results and discuss corporate progress for the second quarter 2025.
Live audio of the webcast will be accessible on Day One’s Events on the Day One Media & Investors page. An archived version of the webcast will be available for replay on the News & Events section of the Day One Media & Investors page for 30 days following the event.
About Day One Biopharmaceuticals
Day One Biopharmaceuticals believes when it comes to pediatric cancer, we can do better. The Company was founded to address a critical unmet need: the dire lack of therapeutic development in pediatric cancer. Inspired by “The Day One Talk” that physicians have with patients and their families about an initial cancer diagnosis and treatment, Day One aims to re-envision cancer drug development and redefine what’s possible for all people living with cancer – regardless of age – starting from day one.
Day One partners with leading clinical oncologists, families, and scientists to identify, acquire, and develop important targeted cancer treatments. The Company’s pipeline includes tovorafenib (OJEMDA™) and DAY301.
Day One is based in Brisbane, California. For more information, please visit www.dayonebio.com or find the Company on LinkedIn or X.
Day One uses its Investor Relations website (ir.dayonebio.com), its X handle (x.com/DayOneBio), and LinkedIn Home Page (linkedin.com/company/dayonebio) as a means of disseminating or providing notification of, among other things, news or announcements regarding its business or financial performance, investor events, press releases, and earnings releases, and as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD.
DAY ONE MEDIA
Laura Cooper, Head of Communications
media@dayonebio.com
DAY ONE INVESTORS
LifeSci Advisors, PJ Kelleher
pkelleher@lifesciadvisors.com
FAQ
When is Day One Biopharmaceuticals (DAWN) reporting Q2 2025 earnings?
How can investors access Day One Biopharmaceuticals' Q2 2025 earnings call?
How long will Day One Biopharmaceuticals' Q2 2025 earnings call replay be available?
What will Day One Biopharmaceuticals (DAWN) discuss in their Q2 2025 earnings call?
